Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 661-676

  Luque Rojas, María Jesús ^a   Galeano, Pablo ^b   Suárez, Juan ^a   Araos, Pedro ^a   Santín, Luis J ^c   De Fonseca, Fernando Rodríguez ^a   Calvo, Eduardo Blanco ^a,c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Cocaine; dopamine; endocannabinoid system; quinpirole; stereotyped behaviour

Indexed keywords

[1,1' BIPHENYL] 3 YL CARBAMIC ACID CYCLOHEXYL ESTER; ACYLGLYCEROL LIPASE; COCAINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ENDOCANNABINOID; ESTERASE INHIBITOR; FATTY ACID AMIDASE; QUINPIROLE; UNCLASSIFIED DRUG; URB 602;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOURAL SENSITIZATION; CONDITIONED REFLEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; ENZYME DEGRADATION; ENZYME INHIBITION; HABITUATION; HYPERACTIVITY; IMMOBILIZATION; JUMPING; LOCOMOTION; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR PERFORMANCE; PSYCHOPHARMACOLOGY; REARING; SENSITIZATION; STEREOTYPY;

ANIMALS; BENZAMIDES; CARBAMATES; DOPAMINE AGONISTS; ENDOCANNABINOIDS; MALE; MICE; MICE, INBRED C57BL; PSYCHOMOTOR AGITATION; QUINPIROLE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STEREOTYPED BEHAVIOR;

EID: 84874606272     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000569     Document Type: Article

References (62)

1. Adamczyk P, Miszkiel J, McCreary AC, Filip M, et al. (2012). The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Research 1444, 45-54.
2. Adermark L, Lovinger DM (2007). Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proceedings of the National Academy of Sciences USA 104, 20564-20569.
3. Adermark L, Talani G, Lovinger DM (2009). Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. European Journal of Neuroscience 29, 32-41.
4. Arnold JC (2005). The role of endocannabinoid transmission in cocaine addiction. Pharmacology, Biochemistry, and Behavior 81, 396-406. (Pubitemid 40812406)
5. Beltramo M, de Fonseca FR, Navarro M, Calignano A, et al. (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. Journal of Neuroscience 20, 3401-3407. (Pubitemid 30263155)
6. Blanco E, Bilbao A, Luque-Rojas MJ, Palomino A, et al. (2012a). Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology 220, 27-42.
7. Blanco E, Campos-Sandoval JA, Palomino A, Luque-Rojas MJ, et al. (2012b). Cocaine modulates both glutaminase gene expression and glutaminase activity in the brain of cocaine-sensitized mice. Psychopharmacology 219, 933-944.
8. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, et al. (2009). Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766.
9. Chefer VI, Shippenberg TS (2002). Changes in basal and cocaine-evoked extracellular dopamine uptake and release in the rat nucleus accumbens during early abstinence from cocaine : quantitative determination under transient conditions. Neuroscience 112, 907-919. (Pubitemid 34667055)
10. Colombo G, Serra S, Vacca G, Carai MA, et al. (2005). Endocannabinoid system and alcohol addiction : pharmacological studies. Pharmacology, Biochemistry, and Behaviour 81, 369-380. (Pubitemid 40807134)
11. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences USA 98, 9371-9376. (Pubitemid 32743923)
12. Cravatt BF, Giang DK, Mayfield SP, Boger DL, et al. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87. (Pubitemid 26374593)
13. Crunelle CL, van de Giessen E, Schulz S, Vanderschuren LJ, et al. (2011). Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addiction Biology. Published online : 29 September 2011. doi:10.1111/j.1369-1600.2011.00369.x.
14. Davis MD, Heffner TG, Cooke LW (1997). Dopamine agonist-induced inhibition of neurotransmitter release from the awake squirrel monkey putamen as measured by microdialysis. Journal of Neurochemistry 68, 659-666. (Pubitemid 27044727)
15. de Haas R, Seddik A, Oppelaar H, Westenberg HG, et al. (in press). Marked inbred mouse strain difference in the expression of quinpirole induced compulsive like behavior based on behavioral pattern analysis. European Neuropsychopharmacology. Published online : 13 February 2012. doi :10.1016/j.euroneuro.2012.01.003.
16. de Vries TJ, Shaham Y, Homberg JR, Crombag H, et al. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine 7, 1151-1154. (Pubitemid 33010025)
17. di Marzo V, Fontana A, Cadas H, Schinelli S, et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
18. Eilam D, Talangbayan H, Canaran G, Szechtman H (1992). Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. Psychopharmacology 106, 447-454.
19. Fernandez-Espejo E, Viveros MP, Núñ ez L, Ellenbroek BA, et al. (2009). Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology 206, 531-549.
20. Ferrer B, Asbrock N, Kathuria S, Piomelli D, et al. (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. European Journal of Neuroscience 18, 1607-1614. (Pubitemid 37215113)
21. Ferrer B, Gorriti MA, Palomino A, Gornemann I, et al. (2007). Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. European Journal of Pharmacology 559, 180-183. (Pubitemid 46295416)
22. Gardner EL (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacology, Biochemistry, and Behavior 81, 263-284. (Pubitemid 40807127)
23. Gerdeman G, Lovinger DM (2001). CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. Journal of Neurophysiology 85, 468-471. (Pubitemid 32062158)
24. Gerdeman GL, Schechter JB, French ED (2008). Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology 33, 2747-2759.
25. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114. (Pubitemid 39486563)
26. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, et al. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience 2, 358-363. (Pubitemid 30491279)
27. Giuffrida A, Piomelli D (2000). The endocannabinoid system: A physiological perspective on its role in psychomotor control. Chemistry and Physics of Lipids 108, 151-158.
28. Glass M, Brotchie JM, Maneuf YP (1997). Modulation of neurotransmission by cannabinoids in the basal ganglia. European Journal of Neuroscience 9, 199-203. (Pubitemid 27091099)
29. Gorriti MA, Ferrer B, del Arco I, Bermudez-Silva FJ, et al. (2005). Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Pharmacology, Biochemistry, and Behavior 81, 71-77. (Pubitemid 40718954)
30. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. European Journal of Pharmacology 365, 133-142. (Pubitemid 29070757)
31. Hnasko TS, Sotak BN, Palmiter RD (2007). Cocaineconditioned place preference by dopamine-deficient mice is mediated by serotonin. Journal of Neuroscience 27, 12484-12488. (Pubitemid 350127797)
32. Hohmann AG, Suplita RL, Bolton NM, Neely MH, et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-1112. (Pubitemid 40910518)
33. Jung EY, Shim I (2011). Differential DAergic control of D1 and D2 receptor agonist over locomotor activity and GABA level in the striatum. Experimental Neurobiology 20, 153-157.
34. Kathuria S, Gaetani S, Fegley D, Valiño F, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine 9, 76-81. (Pubitemid 36098263)
35. Ledent C, Valverde O, Cossu G, Petitet F, et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404.
36. Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, et al. (2005). Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaineinduced behavioural sensitization. European Neuropsychopharmacology 15, 31-37. (Pubitemid 39574397)
37. Li X, Hoffman AF, Peng XQ, Lupica CR, et al. (2009). Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology 204, 1-11.
38. Long LE, Chesworth R, Huang XF, McGregor IS, et al. (2010). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology 13, 861-876.
39. Luchicchi A, Lecca S, Carta S, Pillolla G, et al. (2010). Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area : involvement of PPAR-alpha nuclear receptors. Addiction Biology 15, 277-288.
40. Maldonado R, Rodriguez de Fonseca F (2002). Cannabinoid addiction : behavioral models and neural correlates. Journal of Neuroscience 22, 3326-3331. (Pubitemid 37465736)
41. Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, et al. (2008). Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33, 1667-1679. (Pubitemid 351684717)
42. Navarro G, Carriba P, Gand́a J, Ciruela F, et al. (2008). Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-proteincoupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Scientific World Journal 8, 1088-1097.
43. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, et al. (1988). The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Research 451, 59-68.
44. O'Neill C, Evers-Donnelly A, Nicholson D, O'Boyle KM, et al. (2009). D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors : studies using fast cyclic voltammetry. Journal of Neurochemistry 108, 545-551.
45. Orio L, Edwards S, George O, Parsons LH, et al. (2009). A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. Journal of Neuroscience 29, 4846-4857.
46. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nature Reviews. Neuroscience 4, 873-884. (Pubitemid 37351427)
47. Placzek EA, Okamoto Y, Ueda N, Barker EL (2008). Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. Neuropharmacology 55, 1095-1104.
48. Rasmussen BA, Kim E, Unterwald EM, Rawls SM (2009). Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB(1)-dopamine D(2) receptor mechanism. Brain Research 1260, 7-14.
49. Ritz MC, Cone EJ, Kuhar MJ (1990). Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters : A structure-activity study. Life Sciences 46, 635-645. (Pubitemid 20056887)
50. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, et al. (1998). Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiology of Disease 5, 483-501. (Pubitemid 29075847)
51. Rodriguez de Fonseca F, Gorriti MA, Bilbao A, Escuredo L, et al. (2001). Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotoxicity Research 3, 23-35. (Pubitemid 32717293)
52. Rodriguez de Fonseca F, Mart?́n Calderón JL, Mechoulam R, Navarro M (1994). Repeated stimulation of D1 dopamine receptors enhances (x)-11-hydroxy-delta 8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats. Neuroreport 5, 761-765.
53. Scherma M, Fadda P, Le Foll B, Forget B, et al. (2008). The endocannabinoid system: A new molecular target for the treatment of tobacco addiction. CNS and Neurological Disorders Drug Targets 7, 468-481.
54. Solinas M, Goldberg SR, Piomelli D (2008). The endocannabinoid system in brain reward processes. British Journal of Pharmacology 154, 369-383. (Pubitemid 351670594)
55. Solinas M, Yasar S, Goldberg SR (2007). Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacological Research 56, 393-405. (Pubitemid 350030891)
56. Soria G, Mendizábal V, Touriño C, Robledo P, et al. (2005). Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30, 1670-1680. (Pubitemid 43086024)
57. Starr BS, Starr MS (1986). Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390. Pharmacology, Biochemistry, and Behavior 24, 837-839. (Pubitemid 16074754)
58. Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778. (Pubitemid 27375156)
59. Thiemann G, Watt CA, Ledent C, Molleman A, et al. (2009). Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behavioural Brain Research 200, 60-67.
60. Wang J, Ueda N (2008). Role of the endocannabinoid system in metabolic control. Current Opinion in Nephrology and Hypertension 17, 1-10. (Pubitemid 350295190)
61. Xi ZX, Peng XQ, Li X, Song R, et al. (2011). Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nature Neuroscience 14, 1160-1166.
62. Xi ZX, Spiller K, Pak AC, Gilbert J, et al. (2008). Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects : experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 33, 1735-1745. (Pubitemid 351684714)